Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion lung cancer
Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion lung cancer
TQB2922 combination shows high response rates in EGFR-mutant lung cancer after tyrosine kinase inhibitor resistance
SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer
Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2-mutant lung cancer
Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer
Distinct lung microbiome patterns identified in Portuguese patients with lung cancer
Artificial intelligence PD-L1 scoring matches pathologists and improves reproducibility in lung cancer testing
T-cell engagers in lung cancer: Strategies to prevent and manage toxicities
Education and training in breast cancer care
Low-dose CT screening reduces lung cancer mortality and improves survival in broad populations
Cracking the code: Bispecific immunotherapy in small cell lung cancer
ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC